ZHBIO(300653)2025-04-21 08:50Financial Performance - The company's revenue for Q1 2025 was ¥97,415,845.21, an increase of 8.68% compared to ¥89,634,394.36 in the same period last year[5] - Net profit attributable to shareholders decreased by 34.06% to ¥26,626,723.19 from ¥40,381,480.54 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥23,835,843.45, down 32.13% from ¥35,121,314.44 in the previous year[5] - Basic and diluted earnings per share decreased by 31.82% to ¥0.15 from ¥0.22 year-on-year[5] - Net profit for the current period was ¥26,626,723.19, a decrease of 34.1% from ¥40,381,480.54 in the previous period[22] Operating Costs and Expenses - Operating costs rose by 62.96% to ¥18,548,598.03 compared to ¥11,382,167.75 in the same period last year, primarily due to increased sales volume[9] - Sales expenses increased by 52.42% to ¥32,679,942.53 from ¥21,440,976.21 year-on-year, attributed to targeted marketing efforts[9] - Total operating costs increased to ¥69,470,342.54, up 45.2% from ¥47,887,035.39 in the previous period[21] - Research and development expenses rose to ¥10,539,502.19, compared to ¥8,241,068.59 in the previous period, reflecting a 28% increase[21] Cash Flow and Liquidity - Operating cash flow increased by 6.97% to ¥38,947,811.13 compared to ¥36,410,107.03 in the same period last year[5] - Cash flow from operating activities was not detailed in the provided content, but is critical for assessing liquidity and operational efficiency[23] - Operating cash inflow for the current period was $113,607,783.91, up from $92,635,155.96 in the previous period, representing a growth of approximately 22.6%[24] - Net cash flow from operating activities increased to $38,947,811.13 from $36,410,107.03, reflecting a rise of about 6.9%[24] - Cash and cash equivalents decreased from 116,837,501.64 CNY to 66,588,190.74 CNY, a decline of approximately 43%[17] Assets and Equity - Total assets at the end of the reporting period were ¥1,011,700,820.47, a 3.22% increase from ¥980,113,621.99 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 3.00% to ¥915,410,854.93 from ¥888,784,131.74 at the end of the previous year[5] - Total current assets increased from 712,700,493.26 CNY to 749,093,740.23 CNY, an increase of about 5.1%[17] - Total liabilities rose to ¥96,289,965.54, compared to ¥91,329,490.25 in the previous period, marking a 5.3% increase[19] - Total equity attributable to shareholders increased to ¥915,410,854.93 from ¥888,784,131.74 in the previous period[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,966[11] - The largest shareholder, Mibohai, holds 33.87% of shares, totaling 60,961,500 shares, with 16,000,000 shares pledged[11] - Longwood Biotechnologies Inc. is the second-largest shareholder, holding 7.67% of shares, totaling 13,811,874 shares[11] - The company has no preferred shareholders as of the reporting period[13] - The total number of shareholders with voting rights restored for preferred shares is 0[11] Inventory and Fixed Assets - The total inventory decreased from 35,183,154.31 CNY to 28,257,139.60 CNY, a decline of approximately 19.7%[17] - The total fixed assets decreased from 228,744,485.59 CNY to 224,843,942.51 CNY, a decline of about 1.7%[17] Other Financial Activities - The company reported a significant increase in other operating income, which rose by 2611.34% to ¥29,840.47 from ¥1,100.58 in the previous year[9] - Cash inflow from investment activities decreased to $293,907,815.97 from $376,006,483.59, a decline of approximately 21.9%[25] - Net cash flow from investment activities was negative at -$88,226,053.24, compared to a positive $75,754,219.36 in the previous period[25] - The company did not report any cash inflow from financing activities during this period[25] - The first quarter report was not audited, indicating that the financial data may be subject to further review[26]